New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron…
New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron…